Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q1 results.
Earnings per share rose 5.56% year over year to ($0.51), which missed the estimate of ($0.42).
Revenue of $24,328,000 higher by 22.71% year over year, which beat the estimate of $23,540,000.
The upcoming fiscal year's revenue expected to be between $117,000,000 and $121,000,000.
Details Of The Call
Date: May 10, 2021
Time: 08:30 AM
Company's 52-week high was at $26.98
Company's 52-week low was at $10.84
Price action over last quarter: down 1.87%
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.